MedTrace Logo

A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA)

NCT01116141 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2013-04-15

No results posted yet for this study

Summary

The purpose of this study is to determine if CH-4051 is a safe and effective treatment for rheumatoid arthritis.

Conditions

Interventions

DRUG

CH-4051

Different doses CH-4051 to be compared

DRUG

Methotrexate (MTX)

20 mg MTX weekly

DRUG

Folic Acid

1 mg folic acid daily

Sponsors & Collaborators

  • Chelsea Therapeutics

    lead INDUSTRY

Principal Investigators

  • Arthur A Kavanaugh, MD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-04-30
Completion
2012-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01116141 on ClinicalTrials.gov